Bank of New York Mellon’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Bank of New York Mellon’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-60,405	Closed	-$33K	–	4406
2016 Q3	$33K	Sell	60,405 -12,522	-17%	-$5.72K	﹤0.01%	4184
2016 Q2	$43K	Sell	72,927 -172,632	-70%	-$184K	﹤0.01%	4200
2016 Q1	$358K	Buy	245,559 +1,187	+0.5%	+$2.34K	﹤0.01%	3567
2015 Q4	$782K	Buy	244,372 +17,983	+8%	+$86.5K	﹤0.01%	3316
2015 Q3	$1.42M	Sell	226,389 -6,216	-3%	-$58.1K	﹤0.01%	2960
2015 Q2	$2.31M	Buy	232,605 +71,850	+45%	+$629K	﹤0.01%	2810
2015 Q1	$1.19M	Buy	160,755 +7,075	+5%	+$47.6K	﹤0.01%	3208
2014 Q4	$822K	Buy	153,680 +2,676	+2%	+$13.7K	﹤0.01%	3411
2014 Q3	$760K	Buy	151,004 +1,770	+1%	+$10.9K	﹤0.01%	3448
2014 Q2	$1M	Buy	149,234 +110,049	+281%	+$700K	﹤0.01%	3311
2014 Q1	$284K	Buy	39,185 +7,769	+25%	+$46.1K	﹤0.01%	3757
2013 Q4	$118K	Buy	+31,416	New	+$122K	﹤0.01%	3986

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

CDH

Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

MBT

Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return

MPI

Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Bank of New York Mellon's NWBO Position: Q4 2016 in Review

Bank of New York Mellon sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 60,405 shares — an estimated $33K sold.

Bank of New York Mellon first reported a position in NWBO in Q4 2013 and held it in 12 quarters. The position peaked at $2.31M in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

Bank of New York Mellon reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
Bank of New York Mellon sold 60,405 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $33K.
Bank of New York Mellon first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 12 quarters.
Bank of New York Mellon's Northwest Biotherapeutics, Inc. Common stock position peaked at $2.31M in Q2 2015.
8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Bank of New York Mellon's 13F filing for Q4 2016, filed 13 Feb 2017.